This information is intended for media professionals and investors
+61 2 8876 6162
Medtronic Acquires Image-Guided Neurologics; Broadens Portfolio Of Products For Improved Deep Brain Stimulation Surgical Procedures
Frameless DBS lead placement shown to improve patient comfort, decrease operating time
MINNEAPOLIS – Aug. 30, 2005 – Medtronic, Inc. (NYSE: MDT), today announced that it has acquired Image-Guided Neurologics (IGN) of Melbourne, Fla., a privately held company that specializes in precision navigation and delivery technologies for brain surgery. Specific terms of the agreement were not disclosed. The IGN product line, which includes the NexFrameÔ disposable, “frameless” stereotactic head frame, strengthens Medtronic’s leadership position in deep brain stimulation (DBS) by offering instruments that simplify the procedure for surgeons and improve patient comfort during surgery.
The traditional surgical approach to implanting the leads of Medtronic’s Activa® Therapy neurostimulation system for a DBS procedure involves attaching a stereotactic head frame to the patient. The metal frame allows surgeons to accurately guide the leads to a specific location within the brain, but does not allow patient mobility during a procedure that can last several hours. In contrast, the NexFrame replaces the heavy frame with a small, disposable guidance device that is more comfortable, less stressful on the neck and allows the patient to move and change positions during surgery.
The NexFrame is used in conjunction with image-guided surgery systems that provide surgeons with real-time tracking and verification of the DBS lead’s trajectory and location within the brain. Use of frameless technology can reduce operating time by as much as 90 minutes. Because the frame is disposable, which eliminates the need to sterilize and reset the traditional frame system, surgeons have the opportunity to perform multiple operations each day.
“We know that many neurosurgeons are more comfortable performing image-guided surgical procedures than using traditional stereotactic head frames,” said Todd Langevin, vice president and general manager, global movement disorders, Medtronic Neurological. “We believe the seamless integration of IGN technology with our proven Activa Therapy will increase the number of surgeons who regularly perform these life-altering procedures, while improving the patient experience.”
“Medtronic has been the ideal strategic partner in collaborating with IGN to offer procedural solutions that optimize the delivery of their therapies, accelerate market adoption, and enhance patient comfort,” said Rudy Mazzocchi, president and chief executive officer, IGN. “We look forward to the impact this will have on patients worldwide.”
Applying its expertise in precise delivery of electrical stimulation in multiple areas of the body, Medtronic helped pioneer DBS through the development of its Activa Therapy to treat the three most common movement disorders, Parkinson’s disease, essential tremor and dystonia. To date, more than 30,000 patients worldwide have received Activa Therapy. The company is exploring other potential applications for DBS to treat neurological disorders such as epilepsy, obsessive-compulsive disorder and depression.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 29, 2005. Actual results may differ materially from anticipated results.